GORT

Reviews

Psma Pet Imaging — Professor Declan Murphy

Di: Everly

Professor Declan Murphy, MB, BCh, of the Peter MacCallum Cancer Centre, spoke with CancerNetwork® about the rate of equivocal findings in the proPSMA study for patients

ASCO GU 2021: Welcome to the Wild West: The Impact of the

Revisiting Prostate Cancer Recurrence with PSMA PET: Atlas of Typical ...

From the 2020 SUO Meeting, Professor Declan Murphy, of the Peter MacCallum Cancer Centre, spoke with CancerNetwork about the future of PSMA PET/CT imaging and the

Declan Murphy and Michael Hofman join Alicia Morgans to discuss the results from proPSMA study „A prospective randomized multi-center study of the impact of Ga-68 PSMA-PET/CT

conventional imaging, resulted in half the radiation dose to patients and had a greater impact in changing patient management. 28% of men had the treatment plans changed the PSMA

  • PSMA PET Imaging — Professor Declan Murphy
  • Advanced Prostate Cancer — Professor Declan Murphy
  • Cancro della prostata: la PSMA-PET/CT per una diagnosi più
  • Latest updates in PSMA imaging for prostate cancer

Correspondence: Declan G. Murphy, Division of Cancer Surgery, Peter MacCallum Cancer Centre, 305 Grattan Street, Melbourne, Vic. 3002, Australia. e-mail: [email protected]

Professor Declan Murphy, ProPSMA senior author and Director of Genito-urinary (GU) Oncology at Peter Mac said PSMA PET/CT was a “game changer” by detecting disease

Prof Murphy says imaging has played a very dominant (and disruptive) role at APCCC 2022, especially PSMA PET/CT. Declan interviews four imaging experts to hear their

Advanced Prostate Cancer — Professor Declan Murphy

In addition to improving detection, PSMA-PET/CT also had a significant impact on a patient’s treatment plan and disease management. According to senior author Declan

This is secondary to PSMA PET/CT being more strongly recommended, routine extended pelvic lymph node dissection for high-risk patients no longer recommended, and nomograms no longer being emphasized for intermediate

Dr. Declan Murphy then took the pro approach for PSMA PET/CT for initial staging, emphasizing that PSMA PET/CT has established itself for its accuracy in regional disease, distant disease,

Declan Murphy MD, APCCC 2019 imaging modalities for node positive but non metastatic prostate cancer patients, Declan Murphy, Alicia Morgans, staging pelvic lymph nodes, PSMA

Declan Murphy and Michael Hofman join Alicia Morgans to discuss the results from proPSMA study „A prospective randomized multi-center study of the impact of Ga-68 PSMA-PET/CT

Prof Murphy says imaging has played a very dominant (and disruptive) role at APCCC 2022, especially PSMA PET/CT. Declan interviews four imaging experts to hear their thoughts.

Professor Murphy is a Founding Director of Cancer Specialists, a specialist multidisciplinary cancer practice comprising top specialists from Peter Mac. Professor Murphy is very active on

Declan Murphy, MB, BCh, shares his thoughts on the potential for prostate-specific membrane antigen PET/CT to impact outcomes for patients with localized and high

Re: 18F-Fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in Patients with Early Biochemical Recurrence After Prostatectomy: A Prospective, Single-centre, Single-arm, Comparative

It also provided lower radiation exposure, and informed more effective management changes of prostate cancer than conventional imaging. Professor Declan Murphy, ProPSMA senior author and Director of Genito

PSMA PET Imaging for Prostate Cancer | Kettering Health

Professor Declan Murphy, ProPSMA senior author and Director of Genito-urinary (GU) Oncology at Peter Mac says “PSMA PET/CT is a game changer, detecting disease that previous medical scanning technology failed to

EAU 2022 Declan Murphy the initial results of the LuTectomy trial, LuTectomy, a single-arm study of the dosimetry, safety, and potential benefit of 177Lu-PSMA-617 prior to radical prostatectomy

In December 2020, the FDA approved Gallium 68 PSMA-11 (Ga 68 PSMA-11), the first drug for PET imaging of PSMA-positive lesions in men with prostate cancer. “The

Declan Murphy, MB, BCH, BaO, FRACS, FRCS, Urol, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the latest updates in prostate-specific membrane

Declan Murphy and Michael Hofman join Alicia Morgans to discuss the results from proPSMA study „A prospective randomized multi-center study of the impact of Ga-68 PSMA-PET/CT

PSMA is highly overexpressed by the prostate cancer cells, up to 100- or 1000-fold above normal cells. Additionally, up to 95% of prostate cancer cells express PSMA,

Declan Murphy MD, APCCC 2019 imaging modalities for node positive but non metastatic prostate cancer patients, Declan Murphy, Alicia Morgans, staging pelvic lymph nodes, PSMA

Dosimetry of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes J

Declan Murphy and Michael Hofman join Alicia Morgans to discuss the results from proPSMA study „A prospective randomized multi-center study of the impact of Ga-68

Declan Murphy is Consultant Urologist, Director of Genitourinary (GU) Oncology, and Director of Robotic Surgery at the Peter MacCallum Cancer Centre, Melbourne, Australia, and Professorial Fellow at the Sir Peter MacCallum

Prof Murphy says imaging has played a very dominant (and disruptive) role at APCCC 2022, especially PSMA PET/CT. Declan interviews four imaging experts to hear their thoughts. Nuclear Medicine physicians Professor